Friday, 16 October 2026European Markets
ExploreSearch
ViaNews EU
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· November 3, 2025

Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth

View original at globenewswire.com
Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth Dublin, Nov…
Opening lines of the source · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • The traditional genetic testing market is growing in volume and the number of tests, creating new opportunities and challenges for the industry

    80% confidence

  • Lower pricing combined with new knowledge about genetics in health and disease is driving the genetic testing industry to record growth

    80% confidence

  • The report covers 14 countries and 5 regions with detailed market breakouts

    80% confidence

  • Advances in genomics, aging populations, pharmacogenomics, oncology liquid biopsies, fertility testing, and rising DTC adoption are key drivers of genetic testing market growth for 2025-2030

    80% confidence

  • The genetic testing market has unlimited growth potential and has crossed the chasm, now growing in every area

    80% confidence
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biopharma Catalyst Cluster: Late-Stage Readouts and Regulatory Milestones
October 2026 brings a dense run of Phase 3 wins (ALOFT-IPF, RESTORE-3), new data presentations (Roche, Bayer, Lilly, Vertex, Galderma) and regulatory steps (FDA acceptance of Roche's vamikibart BLA, Scholar Rock's EMA resubmission). The next big catalyst is the ivonescimab FDA PDUFA date on 2026-11-14. Obesity combination studies (REDEFINE 4, TOGETHER-PsO) and the 2027 Maritime-1 completion point to more catalysts ahead. QAIAx's speculative AI-linked trial claims (the QIII pilot, targeted for 2027) are an unrelated micro-cap sideshow with weak evidence, and have little in common with the large-cap pipeline news.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,986
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,986 facts checked against source5,378 source documents archived
Query this data → isubstrate.com
Genetic Testing Market Research Report 2025-2030: Advances in Genomics, Aging Populations, Pharmacogenomics, Oncology Liquid Biopsies, Fertility Testing, and Rising DTC Adoption Driving Growth — Source | Via News | ViaNews EU